Description:
Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2011. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb.
- Molecular Weight: 459.506
- Molecular Formula: C25H25N5O4
Purity: 0.98
Canonical SMILES:
COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
InChI:
InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
InChIKey: QNZCBYKSOIHPEH-UHFFFAOYSA-N
- Boiling Point: 770.5±60.0 °C at 760 mmHg
- Solubility: 0.11mg/mL
- Appearance: White powder
- Application: Factor Xa Inhibitors
Synonyms:
BMS-562247-01; BMS 562247-01; BMS562247-01; brand name: Eliquis
More details are to be found on supplier website
